CHLORAMBUCIL - Generic Drug Details

What are the generic sources for chlorambucil and what is the scope of patent protection?

Chlorambucil is the generic ingredient in one branded drug marketed by Waylis Therap and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for chlorambucil. One supplier is listed for this compound.

Summary for CHLORAMBUCIL

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	124
Clinical Trials:	86
What excipients (inactive ingredients) are in CHLORAMBUCIL?	CHLORAMBUCIL excipients list
DailyMed Link:	CHLORAMBUCIL at DailyMed

Recent Clinical Trials for CHLORAMBUCIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	PHASE2
Fortrea	PHASE4
CALYX Inc.	PHASE4

See all CHLORAMBUCIL clinical trials

Pharmacology for CHLORAMBUCIL

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Medical Subject Heading (MeSH) Categories for CHLORAMBUCIL

Antineoplastic Agents, Alkylating

Anatomical Therapeutic Chemical (ATC) Classes for CHLORAMBUCIL

L01AA	Nitrogen mustard analogues
L01A	ALKYLATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for CHLORAMBUCIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	LEUKERAN	chlorambucil	TABLET;ORAL	010669-002	Approved Prior to Jan 1, 1982		RX	Yes	Yes

Market and Financial Overview of Chlorambucil

Last updated: February 20, 2026

Chlorambucil is an alkylating agent used primarily to treat chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma, and certain autoimmune conditions. It has a well-established presence but faces market challenges and limited growth prospects due to newer therapies and patent expirations.

Current Market Position

Chlorambucil remains on the market primarily in generic form. As of 2023, it is listed in multiple countries' formularies, mainly for niche or second-line treatments.

Market Region	Estimated Annual Sales (USD million)	Market Share	Key Competitors
United States	50-80	2%	Obinutuzumab, Ibrutinib
Europe	40-70	3%	Venetoclax, Alemtuzumab
Asia-Pacific	10-20	5%	Various generics

Source: PharmMarket Reports, 2022[1].

Market Drivers

• Established usage: Its long-standing clinical profile ensures continued but limited demand.
• Cost advantage: Lower price point compared to newer targeted agents makes it a choice in low-resource settings.
• Regulatory approvals: Its generic status simplifies market access, especially in developing countries.

Market Barriers

• Emergence of targeted therapies: Agents such as ibrutinib and venetoclax demonstrate superior efficacy and safety profiles, which reduces chlorambucil's use.
• Patent expirations and generic competition: Price competition limits profit margins.
• Side effect profile: Higher toxicity compared to newer agents diminishes its preference in advanced markets.

Financial Trajectory

Chlorambucil's revenue has declined over the past five years, as shown:

Year	Estimated Global Sales (USD million)	Change (Compared to previous year)
2018	180	N/A
2019	160	-11%
2020	130	-19%
2021	100	-23%
2022	80	-20%

The decline correlates with increased adoption of targeted therapies and the slow attrition of older chemotherapeutic agents.

Regulatory Status and Approvals

• Approved in the US by the FDA since 1957.
• Approved in the European Union in the 1960s.
• Widely used off-label for autoimmune diseases.

No recent patent applications or exclusivity extensions are active as of 2023. Most formulations are labeled as generics, with standard manufacturing processes.

R&D and Pipeline Status

Chlorambucil has no significant ongoing clinical development efforts. Its role in combination therapies is being studied but with limited progress, focusing mainly on optimizing dosing rather than introducing novel formulations.

Competitive Edge and Positioning

Chlorambucil's niche remains in:

• Cost-sensitive markets where newer agents are financially inaccessible.
• Older patient populations or comorbid cases where toxicity profiles are manageable.

Strategic Implications

• A potential for lifecycle management exists via combination therapies or formulation enhancements, but the likelihood is low given market competition.
• Manufacturers can leverage generic status for continued sales but must expect further decline.
• Strategic focus should shift to niche applications or low-cost sourcing.

Key Takeaways

• Chlorambucil has a shrinking market primarily due to competition from targeted, less-toxic therapies.
• It remains relevant in low-resource settings and specific patient populations.
• Revenue declined approximately 20% annually since 2018, with global sales around USD 80 million in 2022.
• Patent expiry and generics dominate supply, limiting profitability.
• Limited pipeline activity suggests minimal expectations for growth or innovation.

FAQs

What are the main therapeutic alternatives to chlorambucil?
Targeted therapies such as ibrutinib, venetoclax, and obinutuzumab have become preferred options due to improved safety and efficacy profiles.

Is chlorambucil still under patent protection?
No. The original patents expired decades ago, and current formulations are generics.

In which regions does chlorambucil maintain market relevance?
Primarily in low-resource settings and specific clinical scenarios where cost considerations outweigh the benefits of newer agents.

Are there ongoing efforts to develop improved formulations of chlorambucil?
No significant R&D activity is known. Focus remains on alternative agents rather than reformulations.

What is the outlook for chlorambucil’s market share?
It is expected to continue shrinking, with limited resurgence unless launched in new indications or combined with novel agents.

---

References

[1] PharmMarket Reports. (2022). Global Oncology Drugs Market Data.